Data from Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium
Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of EOC remains elusive; however, experimental and epidemiologic data suggest a role for hormone-related exposures in ovarian carcinogenesis and risk factor differences by histologic phenotypes and developmental pathways. Research on prediagnosis androgen concentrations and EOC risk has yielded inconclusive results, and analyses incorporating EOC subtypes are sparse. We conducted a pooled analysis of 7 nested case–control studies in the Ovarian Cancer Cohort Consortium to investigate the association between pre-diagnosis circulating androgens [testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS)], sex hormone binding globulin (SHBG), and EOC risk by tumor characteristics (i.e., histology, grade, and stage). The final study population included 1,331 EOC cases and 3,017 matched controls. Multivariable conditional logistic regression was used to assess risk associations in pooled individual data. Testosterone was positively associated with EOC risk (all subtypes combined, ORlog2 = 1.12; 95% confidence interval 1.02–1.24); other endogenous androgens and SHBG were not associated with overall risk. Higher concentrations of testosterone and androstenedione associated with an increased risk in endometrioid and mucinous tumors [e.g., testosterone, endometrioid tumors, ORlog2 = 1.40 (1.03–1.91)], but not serous or clear cell. An inverse association was observed between androstenedione and high grade serous tumors [ORlog2 = 0.76 (0.60–0.96)]. Our analyses provide further evidence for a role of hormone-related pathways in EOC risk, with differences in associations between androgens and histologic subtypes of EOC. Cancer Res; 77(14); 3951–60. ©2017 AACR.
CITE THIS COLLECTION
FUNDING
Department of Defense Ovarian Cancer Research Program
European Commission's Seventh Framework Programme
European Commission
International Agency for Research on Cancer
Danish Cancer Society (Denmark)
Institut Gustave Roussy
Mutuelle Générale de l'Education Nationale
Institut National de la Santé et de la Recherche Médicale
German Cancer Research Center
Federal Ministry of Education and Research
Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research
Hellenic Health Foundation
Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy
National Research Council
Dutch Ministry of Public Health, Welfare and Sports
Netherlands Cancer Registry
LK Research Funds
Dutch Prevention Funds
World Cancer Research Fund
Statistics Netherlands (The Netherlands)
Nordic Centre of Excellence programme on Food, Nutrition and Health
Health Research Fund
Murcia and Navarra
ISCIII RETIC
Swedish Cancer Society
Swedish Research Council and County Councils of Skåne and Västerbotten
Cancer Research UK
Medical Research Council
NIHNCI
NCI
Nurses' Health Study, Nurses' Health Study II
National Cancer Institute
The Woodrow Wilson Foundation/Johnson and Johnson
The Lloyds TSB Charitable Foundation for the Channel Islands
SHARE
Usage metrics
Read the peer-reviewed publication

AUTHORS (26)
- JOJennifer OseEPElizabeth M. PooleHSHelena SchockMLMatti LehtinenAAAlan A. ArslanAZAnne Zeleniuch-JacquotteKVKala VisvanathanKHKathy HelzlsouerJBJulie E. BuringILI-Min LeeATAnne TjønnelandLDLaure DossusATAntonia TrichopoulouGMGiovanna MasalaNON. Charlotte Onland-MoretEWElisabete WeiderpassEDEric J. DuellAIAnnika IdahlRTRuth C. TravisSRSabina Rinaldi